China’s NMPA Accepts Akeso’s Ivonescimab Application for First-Line Biliary Tract Cancer

18 November 2026 | Wednesday | News


Priority Review application is supported by Phase III HARMONi-GI1 results showing median overall survival of 14.9 months with ivonescimab plus chemotherapy versus 12.1 months with durvalumab plus chemotherapy.

Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced that the National Medical Products Administration (NMPA) of China has accepted the supplemental New Drug Application (sNDA) for ivonescimab in combination with chemotherapy for the first-line treatment of patients with locally advanced or metastatic biliary tract cancer (BTC). The application was previously granted Priority Review designation by the NMPA.

This acceptance marks the fourth marketing application submitted for ivonescimab in China and represents the first expansion of ivonescimab's clinical development into gastrointestinal cancers beyond its established lung cancer indications.

The sNDA is supported by results from the randomized, double-blind, multicenter, registrational Phase III HARMONi-GI1 study (AK112-309). The study evaluated ivonescimab plus chemotherapy compared with durvalumab plus chemotherapy, a current global standard of care for first-line BTC. At a pre-specified interim analysis, the study met its primary endpoint of overall survival (OS), demonstrating a statistically significant and clinically meaningful improvement. All key secondary endpoints, including progression-free survival (PFS) and objective response rate (ORR), were also met.

HARMONi-GI1 is the first Phase III study in biliary tract cancer to demonstrate a statistically significant overall survival benefit versus a PD-L1 inhibitor plus chemotherapy regimen. The results were presented as a Late-Breaking Abstract in an oral presentation at the ESMO Presidential Symposium in October 2026.

Key efficacy findings from the HARMONi-GI1 study include:

  • Median overall survival: 14.9 months for the ivonescimab group versus 12.1 months for the durvalumab group (HR 0.75; P=0.0031)
  • Median progression-free survival: 8.4 months for the ivonescimab group versus 5.8 months for the durvalumab group (HR 0.61; P<0.0001)
  • Objective response rate: 53.8% for the ivonescimab group versus 32.5% for the durvalumab group

The global registrational development of ivonescimab in biliary tract cancer is progressing. The Phase II/III study EA2251, conducted in collaboration with Summit Therapeutics, and the ECOG-ACRIN Cancer Research Group, has been initiated. This study will evaluate ivonescimab plus chemotherapy versus pembrolizumab or durvalumab plus chemotherapy in the first-line treatment of advanced BTC. EA2251 represents the seventh international registrational clinical trial of ivonescimab.

News

Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close